Cornelius Gallagher
Pulmonary Disease · Manasquan, NJNPI 1194727982
Payments from drug & device makers
Across 261 payments — averaging $19.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Boehringer Ingelheim$801
- GSK$752
- Harmony Biosciences LLC$274
- Inari Medical, Inc.$192
- Regeneron Healthcare Solutions, Inc.$185
- plus $994 from 15 others
What the payments were for
- Food & beverage$4,949100%
- Education$200%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 63 | $1,771 |
| Boehringer Ingelheim | 43 | $801 |
| GSK | 70 | $752 |
| Harmony Biosciences LLC | 13 | $274 |
| Inari Medical, Inc. | 1 | $192 |
| Regeneron Healthcare Solutions, Inc. | 5 | $185 |
| Sanofi | 12 | $177 |
| Mylan Specialty L.p. | 10 | $148 |
| Jazz Pharmaceuticals Inc. | 9 | $128 |
| Philips North America LLC | 7 | $115 |
| Actelion Pharmaceuticals US, Inc. | 7 | $103 |
| Fisher & Paykel Healthcare Inc | 3 | $100 |
| Amgen | 5 | $68 |
| United Therapeutics Corporation | 6 | $48 |
| Baxter Healthcare | 1 | $24 |
| Advanced Respiratory, Inc | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
| Pfizer | 1 | $14 |
| Insmed, Inc. | 1 | $14 |
| Grifols USA, LLC | 1 | $12 |
| Merck | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FASENRA$461
- BREZTRI$447
- TEZSPIRE$331
- SYMBICORT$331
- FLOWTRIEVER CATHETER, S$192
- CT THROMBECTOMY SYSTEM KIT$192
- BEVESPI AEROSPHERE$161
- DUPIXENT$133
- OFEV$124
- Wakix$123
How this compares
$4,969 in reported general payments places this provider in the 65th percentile of 472 pulmonary disease providers in New Jersey.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 41 | $35,681 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $752 | $35,68141 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 472 pulmonary disease providers in New Jersey.
Other pulmonary disease in Manasquan
- Jeffrey MiskoffManasquan$228K
- Paul FriedmanManasquan$58K
- Reynold PanettieriNew Brunswick$2.5M
- Vinay SikandToms River$1.8M
- Stanley FielMorristown$1.3M
- Joseph HoffmanPark Ridge$1.1M
- Robert SussmanSummit$645K
- Ronaldo GoHackensack$563K
- Deborah GossHackensack$558K
- Sabina HussainNew Brunswick$555K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.